Format

Send to

Choose Destination
Mayo Clin Proc. 2017 May;92(5):838-850. doi: 10.1016/j.mayocp.2017.02.003.

Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Author information

1
Mayo Clinic School of Medicine, Mayo Clinic, Rochester, MN.
2
Department of Neurology, Mayo Clinic, Rochester, MN.
3
Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: rajkumar.vincent@mayo.edu.

Abstract

Monoclonal gammopathies comprise a spectrum of clonal plasma cell disorders that include monoclonal gammopathy of undetermined significance, multiple myeloma, and Waldenström macroglobulinemia. In this review, we outline the epidemiology, etiology, classification, diagnosis, and treatment of monoclonal gammopathy-associated peripheral neuropathy. Monoclonal gammopathy of undetermined significance is relatively common in the general population, with a prevalence of 3% to 4% among individuals older than age 50 years. Therefore, the presence of M protein in a patient with neuropathy does not automatically indicate a causal relationship. Monoclonal gammopathy-associated peripheral neuropathy is often a difficult diagnosis with limited treatment options. Studies addressing the optimal approach to diagnosis and management of this entity are limited. In addition to a review of the literature, we present a diagnostic approach to patients with monoclonal gammopathy-associated peripheral neuropathy and discuss available data and options for treatment.

PMID:
28473042
PMCID:
PMC5573223
DOI:
10.1016/j.mayocp.2017.02.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center